Glaukos ( GKOS ) Q2 Revenue Jumps 30%
Glaukos ( NYSE:GKOS ) , a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%.
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos ( GKOS ) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
What Makes Glaukos ( GKOS ) a New Buy Stock
Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Glaukos ( GKOS ) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
HAMPTON, N.J., June 06, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today announced that Denice M. Torres has been elected to the company's Board of Directors.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Glaukos ( NYSE:GKOS ) , Parsons ( NYSE:PSN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos ( GKOS ) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 33.33% and 3.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates
Ecolab's robust performance across the majority of its segments drives its first-quarter organic sales despite business challenges.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
Here's Why You Should Add Veeva Stock to Your Portfolio Now
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
Earnings Preview: Mettler-Toledo ( MTD ) Q1 Earnings Expected to Decline
Mettler-Toledo (MTD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts
ISRG's first-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Glaukos ( GKOS ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Veracyte ( VCYT ) : Can Its 13.0% Jump Turn into More Strength?
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years - Glaukos ( NYSE:GKOS )
Glaukos GKOS has outperformed the market over the past 5 years by 10.4% on an annualized basis producing an average annual return of 27.01%. Currently, Glaukos has a market capitalization of $5.83 billion.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?
Glaukos reported robust fourth-quarter revenues, but shares plunged 24.8% post-earnings. Can expanding iDose TR adoption and global growth offset competitive pressures and valuation concerns in 2025?
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today - Glaukos ( NYSE:GKOS )
Glaukos GKOS has outperformed the market over the past 5 years by 8.36% on an annualized basis producing an average annual return of 23.52%. Currently, Glaukos has a market capitalization of $6.95 billion.
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery - Glaukos ( NYSE:GKOS )
FDA set an Oct. 20, 2025, review deadline for Glaukos' Epioxa NDA, a next-gen corneal cross-linking therapy for keratoconus. Epioxa met primary efficacy goals with favorable safety, supporting its potential for non-invasive keratoconus treatment.
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition - Glaukos ( NYSE:GKOS )
Glaukos posted Q4 revenue of $105.5 million, beating estimates of $100.49 million. 2025 revenue guidance set at $475 million-$485 million, aligning with analyst expectations. Get two weeks of free access to pro-level trading tools, including news alerts, scanners, and real-time market insights.
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
Glaukos ( GKOS ) Reports Q4 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 6.98% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - CervoMed ( NASDAQ:CRVO ) , Glaukos ( NYSE:GKOS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Meyer Shields upgraded The Travelers Companies, Inc.
What to Expect From These 3 MedTech Stocks This Earnings Season?
Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow.
What Analyst Projections for Key Metrics Reveal About Glaukos ( GKOS ) Q4 Earnings
Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Peering Into Glaukos's Recent Short Interest - Glaukos ( NYSE:GKOS )
Glaukos's GKOS short percent of float has risen 4.05% since its last report. The company recently reported that it has 3.36 million shares sold short, which is 9.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.66 days to cover their ...
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Should iShares S&P Small-Cap 600 Growth ETF ( IJT ) Be on Your Investing Radar?
Style Box ETF report for ...
Should SPDR Portfolio S&P 600 Small Cap ETF ( SPSM ) Be on Your Investing Radar?
Style Box ETF report for ...
Mesa Labs ( MLAB ) Q3 Earnings and Revenues Beat Estimates
Mesa Labs (MLAB) delivered earnings and revenue surprises of 8.98% and 4.91%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Vanguard S&P Small-Cap 600 Growth ETF ( VIOG ) Be on Your Investing Radar?
Style Box ETF report for ...
How Is The Market Feeling About Glaukos? - Glaukos ( NYSE:GKOS )
Glaukos's GKOS short percent of float has risen 18.21% since its last report. The company recently reported that it has 3.04 million shares sold short, which is 8.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.41 days to cover their ...
Should SPDR S&P 600 Small Cap Growth ETF ( SLYG ) Be on Your Investing Radar?
Style Box ETF report for ...
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today - Glaukos ( NYSE:GKOS )
Glaukos GKOS has outperformed the market over the past 5 years by 9.42% on an annualized basis producing an average annual return of 22.7%. Currently, Glaukos has a market capitalization of $8.89 billion.
Intuitive Surgical, Inc. ( ISRG ) Q4 Earnings Surpass Estimates
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of 24.86% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF ( XHE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
NeuroPace ( NPCE ) Soars 9.1%: Is Further Upside Left in the Stock?
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
GKOS Stock Gains Following Positive Study Data on iDose Platform
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market - TransMedics Gr ( NASDAQ:TMDX )
Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate the market for financial gain. Get Real-Time News and Alerts for Your Portfolio
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
